ArticleIndian journal of endocrinology and metabolism
Immunohistochemical Expression of HBME-1 in a Spectrum of Thyroid Neoplasms.
Article in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- C6orf15 expression in thyroid tumors: A promising diagnostic biomarker for the classic variant of papillary thyroid carcinoma.Histology and histopathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Thyroid neoplasms are the most common malignancy of the endocrine system, representing 3.8% of new cancer cases, and it is the ninth most common cancer overall. The immuno-histochemical marker Hector Battifora Mesotheilial-1 (HBME-1) is a monoclonal antibody that now finds its diagnostic utility as a positive marker for well-differentiated thyroid carcinomas. The aim was to study the expression of HBME-1 and to differentiate between malignant and non-malignant lesions by demonstrating their usefulness in the categorisation of thyroid neoplasms. Methods: A prospective study was conducted at a tertiary care centre from August 2022 to May 2023, comprising 25 cases. All thyroidectomy specimens were included. They were subjected to histopathological examination using routine haematoxylin and eosin stain, and further confirmation was made by immuno-histochemical staining for HBME-1. Results: There were a total of 25 cases consisting of 23 (92%) females and two (8%) males. The maximum number of cases was seen in the age group of 21-30 years (27%), followed by 31-40 years (24%) and 41-50 years (24%). The most common thyroid neoplasm noted was the follicular variant of papillary thyroid carcinoma (40%) with HBME-1 being strongly positive for papillary thyroid carcinoma and its variants compared to other tumour sub-types, where it shows diffuse and focal expression. Conclusion: HBME-1, due to its high sensitivity, can be significantly used as a marker for identification and differentiation, particularly papillary thyroid carcinoma. However, using a panel of markers comprising Galectin-3 and Ck-19 along with HBME-1 increases the accuracy and specificity for the correct diagnosis of thyroid neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.